Answers are grounded in this paper and cite their sources.
In this issue of the Journal, Kastelein et al.1 report the results of a 2-year study comparing daily therapy with 80 mg of simvastatin plus either placebo or 10 mg of ezetimibe on the average change in carotid intima–media thickness in patients with familial hypercholesterolemia. The study, called the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression (ENHANCE) trial, showed no significant between-group differences in any of several end points with respect to intima–media thickness (a commonly used risk surrogate for vascular disease) or clinical results, despite a between-group difference in levels of low-density lipoprotein (LDL) cholesterol of 51 mg . . .
No takes yet. Share an insight, caveat, or question.
Brown et al. (2008) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: